Show simple item record

dc.contributor.authorAlsina, M
dc.contributor.authorTabernero, J
dc.contributor.authorArkenau, HT
dc.contributor.authorSquadroni, M
dc.contributor.authorDoi, T
dc.contributor.authorFaustino, C
dc.contributor.authorGhidini, M
dc.contributor.authorMansoor, Was
dc.contributor.authorShitara, K
dc.contributor.authorVan Cutsem, E
dc.contributor.authorCausse-Amellal, N
dc.contributor.authorLeger, C
dc.contributor.authorSkanji, D
dc.contributor.authorIlson, D
dc.date.accessioned2019-12-09T17:08:12Z
dc.date.available2019-12-09T17:08:12Z
dc.date.issued2019en
dc.identifier.citationAlsina M, Tabernero J, Arkenau HT, Squadroni M, Doi T, Faustino C, et al. 801P Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS study. Annals of Oncology. 2019;30(Supplement_5).en
dc.identifier.doi10.1093/annonc/mdz247.127en
dc.identifier.urihttp://hdl.handle.net/10541/622522
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz247.127en
dc.titleEfficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): An analysis of the TAGS studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology Department, Vall d'Hebron University Hospital, Barcelonaen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen
refterms.dateFOA2020-01-22T19:53:25Z


Files in this item

Thumbnail
Name:
mdz247.127.pdf
Size:
88.01Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record